Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
Healthcare
$1.71 -0.90%
-$0.01 today
- Market cap
- $118.15M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
52W Low $1.03High $2.98
Volume 9.92M
Average 2.73M
Income Statement
Follow revenue through to earnings.
Revenue
$65,343.00
FY 2025 · Annual
-70.0% YoYOperating Income
-$86.82M
FY 2025 · Annual
Net Income
-$84.95M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 249.24M | 187.65M | 86.68M | 75.62M | 54.21M |
| Selling, General & Admin | 53.75M | 90.19M | 47.58M | 37M | 32.68M |
| Operating Expenses | 302.99M | 277.84M | 144.77M | 112.62M | 86.89M |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| EBITDA | (296.56M) | (270.9M) | (130.39M) | (103.95M) | (81.96M) |
| EBITDA Margin | -16709.7% | -2639.8% | -15671.8% | -47735.2% | -125425.9% |
| Operating Income | (301.22M) | (267.57M) | (143.94M) | (112.4M) | (86.82M) |
| Operating Margin | -16972.3% | -2607.4% | -17300.3% | -51616.9% | -132871.3% |
| Interest Income | 3.36M | 4.78M | 8.13M | 4.77M | 2.42M |
| Interest Expense | 1.94M | 1.25M | 1.22M | 177.83K | 0 |
| Other Income / Expenses | (2.44M) | (12.24M) | 8.82M | 5.14M | 1.88M |
| Income Before Tax | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Pre-Tax Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Net Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| EPS (Basic) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| EPS (Diluted) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| 214.62M | 19.89M | 22.17M | 27.16M | 468.86M | |
| 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
INO Earnings Waterfall · TTM
NASDAQ:INO · Revenue to Net Income
Key Ratios
EPS$-1.71
Gross Margin0.0%
Net Margin0.0%
P/E Ratio9.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$84.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.71, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| FWP | FWP filing | Nov 6, 2026 | |
| 424B5 | 424B5 filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 424B5 | 424B5 filing | Nov 5, 2026 |
How much revenue does INO generate?
Inovio Pharmaceuticals, Inc. (INO) reported $65,343.00 of revenue in fiscal 2025.
Is INO profitable?
Inovio Pharmaceuticals, Inc. (INO) reported -$84.95M of net income, with a net margin of -130000.0%.
Continue the stock analysis
Jump to another research area for this company.